#4 - AbbVie (NYSE:ABBV)
The biopharmaceutical sector can be volatile, but AbbVie Inc. (NYSE: ABBV) stands out as a safe harbor in any market storm. This is a sector that capitalizes on the aging of America which is creating a demographic shift that will only grow in the coming decade.
Since separating from its parent company, Abbott Laboratories (NYSE: ABT) in 2013 to focus exclusively on branded biopharmaceutical products, the company’s revenue and earnings have been anchored by its blockbuster drug, Humira. And with drugs like Rinvoq and Skyrizi now firmly seeded in the market along with a robust clinical pipeline, investors should have little concern about the stability of revenue and earnings in the future.
AbbVie is another Dividend King on this list. However, one way that ABBV stands out among other defensive stocks is its high-yield dividend. As of early 2025, the yield was 3.69%, and the average annualized three-year growth rate for the dividend was 6.04%, nearly double that of inflation.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More - Current Price
- $171.32
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $205.50 (20.0% Upside)
